2006
DOI: 10.1097/01.crd.0000223651.03023.8e
|View full text |Cite
|
Sign up to set email alerts
|

Nebivolol

Abstract: Nebivolol is a beta-blocker under U.S. Food and Drug Administration review for the treatment of hypertension. The unique pharmacologic properties of nebivolol include high specificity for the beta-1 receptor and a nitric oxide-mediated vasodilatory effect. The agent provides significant blood pressure reduction from baseline values as compared with placebo. Clinical trials have demonstrated that nebivolol reduces blood pressure similarly to atenolol, bisoprolol, amlodipine, nifedipine, lisinopril, and hydrochl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2007
2007
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(6 citation statements)
references
References 63 publications
(98 reference statements)
0
6
0
Order By: Relevance
“…25 Nebivolol has a higher degree of beta-1 selectivity than any other beta-blocker, explaining the minimal effects noted on the airways of asthmatic patients or insulin sensitivity in those with diabetes. 26 Metabolism and elimination of nebivolol is almost entirely through hepatic cytochrome P450 enzymes, although the minimal amount of drug excreted unchanged in the urine can be important in patients with severe renal impairment. 26 This may explain the higher rate of bradycardia seen in those with low eGFR in our study.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…25 Nebivolol has a higher degree of beta-1 selectivity than any other beta-blocker, explaining the minimal effects noted on the airways of asthmatic patients or insulin sensitivity in those with diabetes. 26 Metabolism and elimination of nebivolol is almost entirely through hepatic cytochrome P450 enzymes, although the minimal amount of drug excreted unchanged in the urine can be important in patients with severe renal impairment. 26 This may explain the higher rate of bradycardia seen in those with low eGFR in our study.…”
Section: Discussionmentioning
confidence: 99%
“…26 Metabolism and elimination of nebivolol is almost entirely through hepatic cytochrome P450 enzymes, although the minimal amount of drug excreted unchanged in the urine can be important in patients with severe renal impairment. 26 This may explain the higher rate of bradycardia seen in those with low eGFR in our study.…”
Section: Discussionmentioning
confidence: 99%
“…(7) Use of nebivolol: nebivolol is a β 1-adrenergic receptor antagonist, a third-generation beta-adrenergic blocker, with vasodilator and antioxidant properties [188, 189]. It has been hypothesized that nebivolol may protect the kidney against CIN through its antioxidant and NO-mediated vasodilator action.…”
Section: Contrast-induced Nephropathymentioning
confidence: 99%
“…Nebivolol is a β 1 receptor antagonist which has vasodilatory and antioxidant effect [116, 117]. After contrast media administration, the pretreated rats with nebivolol had less oxidative stress marker and histological abnormalities compared to those without nebivolol pretreatment [118].…”
Section: Pharmacological Strategies To Prevent Ci-akimentioning
confidence: 99%